SCHEMBL891009

SCHEMBL891009

c1ccc(Nc2ncnc3[nH]cnc23)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTBK1 Q5TCY1 2/20 0.57
TTBK2 Q6IQ55 2/20 0.57
MAPK1 P28482 1/20 0.51
EGFR P00533 11/20 0.50
ABL1 P00519 3/20 0.49
PRKCA P17252 2/20 0.49
ABL2 P42684 1/20 0.49
DAPK3 O43293 1/20 0.49
MAP4K4 O95819 1/20 0.49
ERBB2 P04626 1/20 0.49
PIM1 P11309 1/20 0.49
PRKACA P17612 1/20 0.49
LTK P29376 1/20 0.49
MAPK8 P45983 1/20 0.49
CSNK1A1 P48729 1/20 0.49
RPS6KA3 P51812 1/20 0.49
LIMK1 P53667 1/20 0.49
MAP2K1 Q02750 1/20 0.49
ACVR1 Q04771 1/20 0.49
TYRO3 Q06418 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28048062 0.87 TTBK1 (0.64) TTBK1TTBK2EGFRAURKBHPGD
SCHEMBL4498466 0.83 TTBK1 (0.59) TTBK1TTBK2MAPK1EGFRMAP4K4
SCHEMBL30677302 0.83 EGFR (0.54) TTBK1TTBK2MAPK1EGFRLRRK2
SCHEMBL4921635 0.83 MKNK1 (0.54) TTBK1TTBK2MAPK1EGFRROCK1
SCHEMBL4922514 0.83 MKNK1 (0.61) TTBK1TTBK2MAPK1EGFRROCK1
SCHEMBL4926094 0.83 EGFR (0.54) TTBK1TTBK2MAPK1EGFRLRRK2
SCHEMBL4923801 0.83 TTBK1 (0.59) TTBK1TTBK2EGFRROCK1LRRK2
SCHEMBL10000200 0.82 TTBK1 (0.56) TTBK1TTBK2
SCHEMBL4913660 0.82 TTBK1 (0.63) TTBK1TTBK2EGFRABL1PRKCA
SCHEMBL4917994 0.82 MAPK1 (0.58) MAPK1EGFRABL1ABL2ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110882290-A Application of extract of rhinacanthus nasutus callus, method for inducing and proliferating rhinacanthus nasutus callus and culture medium 大江生医股份有限公司 2020-03-17 CN claimed
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2014-10-09 US claimed
EP-2173173-B1 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES UNIV PALACKEHO (CZ) 2013-07-24 EP claimed
EP-2546387-A1 Adhesion promotion of metal to laminate with a multi-functional compound Enthone, Inc. (US) 2013-01-16 EP claimed
EP-2274460-B1 ADHESION PROMOTION OF METAL TO LAMINATE WITH A MULTI-FUNCTIONAL COMPOUND ENTHONE (US) 2012-10-10 EP claimed
US-8222260-B2 Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives Univerzita Palackego V Olomouci (CZ) 2012-07-17 US claimed
US-20120168075-A1 ADHESION PROMOTION OF METAL TO LAMINATE WITH MULTI-FUNCTIONAL MOLECULAR SYSTEM ENTHONE INC. (US) 2012-07-05 US claimed
EP-2274460-A1 ADHESION PROMOTION OF METAL TO LAMINATE WITH A MULTI-FUNCTIONAL COMPOUND HAFTFORDERUNG VON METALL ZU LAMINATEN MIT EINER MULTIFUNKTIONELLEN Enthone, Inc. (US) 2011-01-19 EP claimed
US-20100190806-A1 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2010-07-29 US claimed
EP-2173173-A2 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES Univerzita palackeho V Olomouci (CZ) 2010-04-14 EP claimed
WO-2009117734-A1 ADHESION PROMOTION OF METAL TO LAMINATE WITH A MULTI-FUNCTIONAL COMPOUND HAFTFORDERUNG VON METALL ZU LAMINATEN MIT EINER MULTIFUNKTIONELLEN ENTHONE INC. (US) 2009-09-24 WO claimed
WO-2009003428-A2 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2009-01-08 WO claimed
US-20050043328-A1 Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) 2005-02-24 US claimed
EP-1419157-A2 HETEROCYCLIC COMPOUND BASED ON N sp 6 /sp −SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) 2004-05-19 EP claimed
WO-2003040144-A2 HETEROCYCLIC COMPOUND BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) 2003-05-15 WO claimed
US-12004509-B2 Co-formulation comprising a plant growth regulator and an oil, and methods of preparing and using said co-formulation INDORAMA VENTURES OXIDES AUSTRALIA PTY LIMITED (AU) 2024-06-11 US disclosed
CN-116806838-A Liquid preparation containing 2-fluoro-N- (3-methoxyphenyl) -7H-purine-6-amine and preparation method and application thereof 郑州郑氏化工产品有限公司 2023-09-29 CN disclosed
US-5021422-A Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins SENETEK PLC (DK) 1991-06-04 US disclosed
EP-0421819-A1 Therapeutic nucleosides THE WELLCOME FOUNDATION LIMITED (GB) 1991-04-10 EP disclosed
EP-0286425-A2 Therapeutic nucleosides THE WELLCOME FOUNDATION LIMITED (GB) 1988-10-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) PRKAG2, PRKAB2, PRKAG1 TTBK1 534/4885TTBK2 638/4885MAPK1 559/4885
US-20050043328-A1 Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds ATIC, UMPS, CCNB1 TTBK1 2189/4885TTBK2 2737/4885MAPK1 2376/4885
US-20100190806-A1 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES DPYD, XDH, APRT TTBK1 3002/4885TTBK2 3026/4885MAPK1 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.